{
  "docId": "019de076-b731-71da-a78f-007719e300bb",
  "docSlug": "1616e8b22ac58e7f024f1153201d610f",
  "documentTitle": "Nuvalent | Investor Presentation Deck | 42 slides",
  "authorId": "nuvalent",
  "authorName": "Nuvalent",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 34,
  "pageCount": 42,
  "prevPage": 33,
  "nextPage": 35,
  "slideType": "traction",
  "function": "show_traction",
  "density": "overcrowded",
  "nDataPoints": 12,
  "notes": "Includes clinical trial data (ARROS-1 Phase 1) with specific patient subgroup outcomes.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-b731-71da-a78f-007719e300bb/34",
  "deckHref": "/decks/019de076-b731-71da-a78f-007719e300bb",
  "deckJsonHref": "/decks/019de076-b731-71da-a78f-007719e300bb.json",
  "deckAnchorHref": "/decks/019de076-b731-71da-a78f-007719e300bb#slide-34",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.15,
        "x": 0.6,
        "y": 0.18
      },
      "kind": "chart",
      "text": "Reduction in ROS1 G2032R Allele",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a0d75c7f-c965-45ff-8aa2-81c5fba5e258",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.2,
        "x": 0.38,
        "y": 0.18
      },
      "kind": "chart",
      "text": "Reduction in Tumor Burden in Cancers with ROS1 G2032R",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e1c86b95-7604-4118-891f-dbc68c91c9f6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.2,
        "x": 0.78,
        "y": 0.5
      },
      "kind": "disclaimer",
      "text": "Data as of 13 Sep 2022, for patients treated by 01 Sep 2022. CNS, central nervous system; ctDNA, circulating tumor deoxyribonucleic acid; NSCLC, non-small cell lung cancer; ORR, objective response rate; PD, progressive disease; PR, partial response; QD, once daily; SD, stable disease; TKI, tyrosine kinase inhibitor.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dc6a8084-2d64-49a2-ba84-9a586cc30159",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.25,
        "x": 0.38,
        "y": 0.55
      },
      "kind": "image",
      "text": "NVL-520 Induced Responses in Intracranial Lesions",
      "attrs": null,
      "subkind": "screenshot",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dc91f43b-e449-4f16-9c7c-70bb324a68de",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.3,
        "x": 0.06,
        "y": 0.54
      },
      "kind": "list",
      "text": "CNS Activity: Intracranial PR in 3/3 patients with measurable (>10 mm) CNS metastases. ORR of 73% (8/11) in response-evaluable patients with history of CNS metastases. No CNS progression observed in any of the 35 treated patients.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "67026248-33a7-420c-a6e1-ead27c7cee5b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.3,
        "x": 0.06,
        "y": 0.24
      },
      "kind": "list",
      "text": "ROS1 Resistance Mutations: Subgroup with known ROS1 G2032R resistance mutation: ORR: 78% (7/9); 100% (9/9) with tumor shrinkage. One patient with ROS1 D2033N with ongoing PR (-40%) pending confirmation.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9ec4ae89-9aca-40f8-8e85-d932c56063bb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.2,
        "x": 0.06,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "Source: Drilon A. et al., EORTC-NCI-AACR 2022.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "44636666-f84a-4fdf-8bf5-48a189ff13fc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.2,
        "x": 0.06,
        "y": 0.12
      },
      "kind": "title",
      "text": "Key Subgroups",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cd9dfe2e-4275-4599-b34b-8714450ac697",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}